Formycon AG (FSB: FYB, Prime Standard) will publish its financial results for the fiscal year 2025 on April 22, 2026. The management board will discuss the company's development, key financial figures, and provide an outlook for the 2026 fiscal year during a conference call broadcast live on the internet that same day at 3:00 PM CEST. The call will be conducted in English, and participants can register at the registration page. After registration, a confirmation email with individual dial-in data will be provided. The presentation and audio broadcast will be accessible via this webcast link. Following a brief presentation, the management board will be available for analysts' questions. The conference call will be recorded and subsequently available on the Formycon website at Formycon's publications page.
In the second quarter of 2026, representatives of Formycon's management board will attend several investor conferences and events. On May 11–12, CFO Enno Spillner will represent the company at the Equity Forum Spring Conference in Frankfurt, Germany. On May 28, Formycon will publish its results for the first quarter of 2026, followed by a conference call and webcast with CEO Dr. Stefan Glombitza, CFO Enno Spillner, CBO Nicola Mikulcik, and CSO Dr. Andreas Seidl. In June, CFO Enno Spillner will attend the Jefferies Global Healthcare Conference in New York City (June 2–4). On June 8, the management board will participate in the mwb research Roundtable via webcast. The Annual General Meeting will be held on June 10 at Haus der Bayerischen Wirtschaft in Munich, Germany, with all board members present. Finally, on June 18, CFO Enno Spillner will attend the UBS Life Sciences Conference in London, UK. A full financial calendar is available at Formycon's investor relations page.
Formycon is a leading independent developer of high-quality biosimilars, focusing on therapies in ophthalmology, immunology, immuno-oncology, and other key disease areas. The company covers nearly the entire value chain from technical development through clinical trials to regulatory approval. For commercialization, Formycon relies on strong, long-term partnerships worldwide. With FYB201 (ranibizumab) and FYB202 (ustekinumab), Formycon already has two biosimilars on the market. Another biosimilar, FYB203 (aflibercept), has been approved by the FDA, EMA, and MHRA. Four pipeline candidates, including FYB208 (dupilumab), are currently in development. Formycon's biosimilars aim to provide broader patient access to highly effective and affordable medicines.
The announcement of these events underscores Formycon's commitment to transparent communication with investors and the financial community. As the biosimilar market continues to grow—global sales are currently around $21 billion and are expected to rise to over $74 billion by 2030—Formycon's progress in developing and commercializing biosimilars positions it to contribute significantly to healthcare cost reduction and patient access. Investors and analysts will be watching closely for updates on pipeline candidates and financial performance during the upcoming conference call and investor meetings.
